0
0
9/29/22 at 2:32pm
Organization
Hcplive.com
Author
Kenny Walter
33 words
0
Comments
The majority of patients treated with systemic therapies were treated with dupilumab, while 3.2% patients received a combination of systemic therapies.
You are the first to view
https://www.hcplive.com/view/covid-19-complication-risk-low-atopic-dermatitis-patients
Create an account
or login to join the discussion